DK3091981T3 - Sammensætninger og fremgangsmåder til behandling af abnorm cellevækst - Google Patents
Sammensætninger og fremgangsmåder til behandling af abnorm cellevækst Download PDFInfo
- Publication number
- DK3091981T3 DK3091981T3 DK15701875.5T DK15701875T DK3091981T3 DK 3091981 T3 DK3091981 T3 DK 3091981T3 DK 15701875 T DK15701875 T DK 15701875T DK 3091981 T3 DK3091981 T3 DK 3091981T3
- Authority
- DK
- Denmark
- Prior art keywords
- abnorm
- compositions
- treatment
- methods
- cell growth
- Prior art date
Links
- 230000010261 cell growth Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925467P | 2014-01-09 | 2014-01-09 | |
| PCT/US2015/010810 WO2015106096A1 (en) | 2014-01-09 | 2015-01-09 | Compositions and methods for treatment of abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3091981T3 true DK3091981T3 (da) | 2021-05-31 |
Family
ID=52434976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15701875.5T DK3091981T3 (da) | 2014-01-09 | 2015-01-09 | Sammensætninger og fremgangsmåder til behandling af abnorm cellevækst |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20150190346A1 (enExample) |
| EP (2) | EP3900726A1 (enExample) |
| JP (5) | JP6647204B2 (enExample) |
| KR (3) | KR20240159639A (enExample) |
| CN (3) | CN115708827A (enExample) |
| AU (4) | AU2015204597B2 (enExample) |
| BR (1) | BR112016016021B1 (enExample) |
| CA (1) | CA2936283C (enExample) |
| DK (1) | DK3091981T3 (enExample) |
| ES (1) | ES2870562T3 (enExample) |
| IL (2) | IL246667B (enExample) |
| MX (2) | MX384259B (enExample) |
| NZ (2) | NZ721934A (enExample) |
| SG (2) | SG10201805890QA (enExample) |
| WO (1) | WO2015106096A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110719782B (zh) * | 2018-05-15 | 2023-02-07 | 江苏豪森药业集团有限公司 | 包含第三代小分子egfr抑制剂的药物组合物及其制备方法 |
| JP2022547358A (ja) * | 2019-09-13 | 2022-11-14 | ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル | 治療組成物、組み合わせ、及び使用方法 |
| CN115348863A (zh) * | 2020-03-27 | 2022-11-15 | 辉瑞公司 | 以2-[(4-{6-[(4-氰基-2-氟苄基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-甲酸或其药学上的盐治疗2型糖尿病或肥胖症或体重过重 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| CN117582504A (zh) * | 2022-08-15 | 2024-02-23 | 海创药业股份有限公司 | 一种治疗卵巢癌的联合用药物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE364374T1 (de) * | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| BRPI0413363A (pt) * | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase |
| WO2006061712A2 (en) * | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
| JP4782239B2 (ja) * | 2007-04-18 | 2011-09-28 | ファイザー・プロダクツ・インク | 異常細胞増殖治療のためのスルホニルアミド誘導体 |
| KR20110042356A (ko) * | 2008-08-13 | 2011-04-26 | 버텍스 파마슈티칼스 인코포레이티드 | 제약 조성물 및 그의 투여 |
| WO2011112922A2 (en) * | 2010-03-11 | 2011-09-15 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
| CA2808501A1 (en) * | 2010-08-23 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof |
| US8591944B2 (en) * | 2011-03-08 | 2013-11-26 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| EP2572731A1 (en) * | 2011-09-26 | 2013-03-27 | Abbott GmbH & Co. KG | Formulations based on solid dispersions |
| JP2017505321A (ja) * | 2014-02-07 | 2017-02-16 | ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． | 異常な細胞成長を処置するための方法および組成物 |
| ES2987376T3 (es) * | 2015-06-29 | 2024-11-14 | Verastem Inc | Composiciones terapéuticas, combinaciones y métodos de uso |
-
2015
- 2015-01-09 KR KR1020247035735A patent/KR20240159639A/ko active Pending
- 2015-01-09 CA CA2936283A patent/CA2936283C/en active Active
- 2015-01-09 KR KR1020227031505A patent/KR20220130251A/ko not_active Ceased
- 2015-01-09 SG SG10201805890QA patent/SG10201805890QA/en unknown
- 2015-01-09 NZ NZ721934A patent/NZ721934A/en unknown
- 2015-01-09 MX MX2016009056A patent/MX384259B/es unknown
- 2015-01-09 DK DK15701875.5T patent/DK3091981T3/da active
- 2015-01-09 EP EP21160977.1A patent/EP3900726A1/en active Pending
- 2015-01-09 WO PCT/US2015/010810 patent/WO2015106096A1/en not_active Ceased
- 2015-01-09 ES ES15701875T patent/ES2870562T3/es active Active
- 2015-01-09 BR BR112016016021-5A patent/BR112016016021B1/pt active IP Right Grant
- 2015-01-09 JP JP2016545782A patent/JP6647204B2/ja active Active
- 2015-01-09 NZ NZ760233A patent/NZ760233A/en unknown
- 2015-01-09 CN CN202211274002.0A patent/CN115708827A/zh active Pending
- 2015-01-09 AU AU2015204597A patent/AU2015204597B2/en active Active
- 2015-01-09 US US14/593,468 patent/US20150190346A1/en not_active Abandoned
- 2015-01-09 CN CN202411889753.2A patent/CN119868364A/zh active Pending
- 2015-01-09 SG SG11201605588YA patent/SG11201605588YA/en unknown
- 2015-01-09 CN CN201580011527.7A patent/CN106102744A/zh active Pending
- 2015-01-09 KR KR1020167021370A patent/KR102444494B1/ko active Active
- 2015-01-09 EP EP15701875.5A patent/EP3091981B1/en active Active
-
2016
- 2016-07-07 IL IL246667A patent/IL246667B/en unknown
- 2016-07-08 MX MX2021008225A patent/MX2021008225A/es unknown
-
2019
- 2019-03-11 US US16/298,907 patent/US20200038331A1/en not_active Abandoned
- 2019-09-17 JP JP2019168245A patent/JP2020007355A/ja active Pending
-
2020
- 2020-07-27 AU AU2020210153A patent/AU2020210153B2/en active Active
-
2021
- 2021-10-05 JP JP2021163957A patent/JP2022001587A/ja not_active Withdrawn
-
2022
- 2022-04-07 IL IL292054A patent/IL292054A/en unknown
- 2022-06-10 US US17/837,891 patent/US20230104303A1/en active Pending
- 2022-10-19 AU AU2022256144A patent/AU2022256144B2/en active Active
-
2023
- 2023-03-01 JP JP2023030912A patent/JP2023065568A/ja not_active Withdrawn
-
2025
- 2025-02-28 JP JP2025031469A patent/JP2025084892A/ja active Pending
- 2025-06-26 AU AU2025204843A patent/AU2025204843A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3102232T3 (da) | Fremgangsmåder og sammensætninger til behandling af abnorm cellevækst | |
| DK3125927T3 (da) | Fremgangsmåder og sammensætninger til immunmodulering | |
| DK3757206T3 (da) | Transduktionsfremgangsmåde og cellebehandling | |
| DK3137605T3 (da) | Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
| DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
| DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3206497T3 (da) | Sammensætninger og fremgangsmåder til behandling af meibomsk kirtel-dysfunktion | |
| DK3092256T3 (da) | Forbindelser og sammensætninger til immunterapi | |
| DK3134130T3 (da) | Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| DK3018183T3 (da) | Halogenolefinbaseret sammensætning og anvendelse deraf | |
| DK3089971T3 (da) | Forbindelser og fremgangsmåder til anvendelse | |
| DK3102189T3 (da) | Sammensætning og fremgangsmåde til at fremme søvn | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3178324T3 (da) | Mikrobicid og fremgangsmåde til fremstilling af samme | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
| DK3143207T3 (da) | Kunstgræs og metode til at fremstille samme | |
| DK3586821T3 (da) | Stamcellestimulerende sammensætninger og metoder | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3261644T3 (da) | Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning |